Payment overview · 2025
General Payments
$411.44
10 reported records · 7 companies
Healthcare provider profile · identity verified
Edward Panousieris, DO
Allopathic & Osteopathic Physicians|Family Medicine · MESQUITE, TX · NPI 1578675864
Verified facts
What the public records show
CMS Open Payments records show Edward Panousieris, DO received $411.44 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.84 | 29.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $119.92 | 29.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.44 | 11.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.68 | 10.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.65 | 8.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.25 | 7.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.66 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $411.44 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.92 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.44 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.65 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.65 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 104 |
| Prednisone | Prednisone | 296 | 154 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 244 | 67 |
| Azithromycin | Azithromycin | 240 | 134 |
| Gabapentin | Gabapentin | 189 | 60 |
| Lisinopril | Lisinopril | 178 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 41 |
| Metformin Hcl Er | Metformin Hcl | 159 | 52 |
| Potassium Chloride | Potassium Chloride | 156 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 44 |
| Losartan Potassium | Losartan Potassium | 148 | 47 |
| Alprazolam | Alprazolam | 138 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 138 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 22 |
| Famotidine | Famotidine | 109 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 15 |
| Metformin Hcl | Metformin Hcl | 101 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 32 |
| Tramadol Hcl | Tramadol Hcl | 100 | 20 |
| Simvastatin | Simvastatin | 94 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 31 |
| Omeprazole | Omeprazole | 91 | 26 |
| Sertraline Hcl | Sertraline Hcl | 91 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 22 |
| Celecoxib | Celecoxib | 74 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 25 |
| Nifedipine Er | Nifedipine | 72 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 23 |
| Finasteride | Finasteride | 70 | 23 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 70 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 22 |
| Ozempic | Semaglutide | 69 | suppressed |
| Bupropion Xl | Bupropion Hcl | 67 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 19 |
| Carvedilol | Carvedilol | 65 | 20 |
| Furosemide | Furosemide | 64 | 27 |
| Eliquis | Apixaban | 63 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 16 |
| Montelukast Sodium | Montelukast Sodium | 61 | 20 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 60 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 42 |
| Allopurinol | Allopurinol | 58 | 18 |
| Terazosin Hcl | Terazosin Hcl | 57 | 15 |
| Valsartan | Valsartan | 55 | 17 |
| Methocarbamol | Methocarbamol | 53 | 15 |
| Jardiance | Empagliflozin | 52 | 14 |
| Levofloxacin | Levofloxacin | 51 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 11 |
| Trazodone Hcl | Trazodone Hcl | 49 | 16 |
| Spironolactone | Spironolactone | 44 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 42 | 13 |
| Fluconazole | Fluconazole | 40 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 16 |
| Methylprednisolone | Methylprednisolone | 38 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Pregabalin | Pregabalin | 35 | 11 |
| Baclofen | Baclofen | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 11 |
| Buspirone Hcl | Buspirone Hcl | 33 | 11 |
| Glimepiride | Glimepiride | 33 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | 11 |
| Bumetanide | Bumetanide | 31 | 11 |
| Ezetimibe | Ezetimibe | 31 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 18 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 31 | suppressed |
| Dexamethasone | Dexamethasone | 30 | 22 |
| Estradiol | Estradiol | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 30 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 23 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | 19 |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | 11 |
| Hydrocortisone | Hydrocortisone | 23 | 13 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Testosterone | Testosterone | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $411.44 · 10 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Cologuard Collection Kit, FREESTYLE LIBRE 3, Korlym, OTEZLA, Ozempic, REPATHA, The Cologuard Plus Collection Kit, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error